In this systematic review and meta-analysis of seven RCTs including 3915 patients, we compared PD-1/PD-L1 inhibitors plus chemotherapy as NAT or AT to chemotherapy alone in patients with resectable stage NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.